MIGUEL ÁNGEL
LÓPEZ RUZ
PROFESOR TITULAR DE UNIVERSIDAD
Hospital de Jerez
Jerez, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Jerez (5)
2022
-
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Viruses, Vol. 14, Núm. 3
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2005
-
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study
HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328